Co-Diagnostics' genetic detection technology on display at international agriculture conference

A presentation by a Bayer – Crop Science rep described the company's successful Multiplex PCR genetic detection

Strand of DNA
The presentation, titled "CoPrimer Assays for Multiplex PCR," was put on by a Bayer representative at the International Plant & Animal Genome XXVIII conference in San Diego

Co-Diagnostics Inc’s (NASDAQ:CODX) BHQplex CoPrimer technology, which is used in diagnostics tests utilizing DNA or RNA, was the star of a presentation from Bayer – Crop Science at an agricultural presentation on Tuesday. 

The presentation, titled "CoPrimer Assays for Multiplex PCR," was put on by a Bayer representative at the International Plant & Animal Genome XXVIII conference this week in San Diego. 

It described a study that involved developing genotyping assays — which detect genetic sequences — using the Utah-based company’s CoPrimer technology. That detection process includes includes multiplex PCR (polymerase chain reaction), a system for detecting multiple genetic sequences all at once, rather than having to do a new test for each particular sequence.

READ: Co-Diagnostics to ring Nasdaq opening bell in San Francisco

"We are excited to announce this third-party validation, the importance of which cannot be overstated, and which further supports our confidence in the uniqueness and superior advantages of our patented CoPrimer platform technology,” CEO Dwight Egan said in a statement. “Bayer’s commitment to a world where more sustainable farming practices and more adaptive, resilient plants are part of the solution to making hunger a thing of the past aligns perfectly with our mission to improve the lives and quality of life in communities across the world.”

Co-Diagnostics’ technology is being licensed by LGC Biosearch Technologies, a biotechnology company based in the UK. 

"With partners like LGC, including their globe-spanning footprint in over 200 countries, and validation from such an important force in the world of agriculture as Bayer, we believe that Co-Diagnostics is better positioned than ever to leverage our technology platform and establishing the Company as a valuable player in the world of AgBio,” Egan said.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Co-Diagnostics

Price: 13.45 USD

Market: NASDAQ
Market Cap: $377.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...


Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read